Instituto Butantan Deal History & Licensing Activity
Instituto Butantan is a life sciences. Over the past three years, Instituto Butantan has been involved in 1 licensing and acquisition transaction, with a primary focus on CAR-T (2 deals).
Deals (12mo)
1
Active Trials
0
Top Modality
CAR-T
Focus Area
Oncology
Instituto Butantan Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Instituto Butantan in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| Undisclosed | IASO Bio | CAR-T | Unknown | license | Apr 2026 |
Instituto Butantan Pipeline Focus
Therapeutic areas and modalities where Instituto Butantan is most active based on deal history and clinical trial data.
See How Your Asset Matches Instituto Butantan's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Oncology assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
CAR-T Benchmarks
Upfront, milestone, and royalty benchmarks for car-t deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Instituto Butantan Licensing & Deal Activity
Instituto Butantan is a life sciences company that has been actively engaged in licensing transactions across the biopharma landscape. With 1 deal over the past three years, Instituto Butantan ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Instituto Butantan include Oncology (2 deals and trials). In terms of modality, Instituto Butantan has shown particular interest in car-t.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Instituto Butantan and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Instituto Butantan's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.